Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enrichment of Activated Fibroblasts as a Potential Biomarker for a Non-Durable Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn's Disease.
Park SK, Lee GY, Kim S, Lee CW, Choi CH, Kang SB, Kim TO, Chun J, Cha JM, Im JP, Ahn KS, Kim SY, Kim MS, Lee CK, Park DI. Park SK, et al. Among authors: kim s, kim sy, kim ms, kim to. Int J Mol Sci. 2023 Sep 30;24(19):14799. doi: 10.3390/ijms241914799. Int J Mol Sci. 2023. PMID: 37834250 Free PMC article.
Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database.
Lee CK, Ha HJ, Oh SJ, Kim JW, Lee JK, Kim HS, Yoon SM, Kang SB, Kim ES, Kim TO, Na SY, Lee J, Kim SW, Koo HS, Park BK, Lee HH, Kim ES, Park JJ, Kwak MS, Cha JM, Ye BD, Choi CH, Kim HJ. Lee CK, et al. Among authors: kim hj, kim sw, kim hs, kim to, kim jw, kim es. J Gastroenterol Hepatol. 2020 May;35(5):760-768. doi: 10.1111/jgh.14855. Epub 2019 Oct 27. J Gastroenterol Hepatol. 2020. PMID: 31498502
Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Kim J, et al. Among authors: kim n, kim ys, kim to, kim es. Inflamm Bowel Dis. 2021 Nov 15;27(12):1931-1941. doi: 10.1093/ibd/izaa361. Inflamm Bowel Dis. 2021. PMID: 33501935
Development of a Clinical and Genetic Prediction Model for Early Intestinal Resection in Patients with Crohn's Disease: Results from the IMPACT Study.
Kang EA, Jang J, Choi CH, Kang SB, Bang KB, Kim TO, Seo GS, Cha JM, Chun J, Jung Y, Kim HG, Im JP, Kim S, Ahn KS, Lee CK, Kim HJ, Kim MS, Park DI. Kang EA, et al. Among authors: kim hg, kim hj, kim s, kim ms, kim to. J Clin Med. 2021 Feb 7;10(4):633. doi: 10.3390/jcm10040633. J Clin Med. 2021. PMID: 33562363 Free PMC article.
The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study.
Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. Ye BD, et al. Among authors: kim yh, kim js, kim to. Therap Adv Gastroenterol. 2021 Jul 5;14:17562848211024769. doi: 10.1177/17562848211024769. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34285716 Free PMC article.
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study.
Shin SY, Park SJ, Kim Y, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Kim DH, Teng D, Kim JH, Kim W, Choi CH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Shin SY, et al. Among authors: kim yh, kim hj, kim w, kim hk, kim dh, kim ys, kim to, kim hs, kim y, kim jw, kim es, kim jh. Intest Res. 2022 Jul;20(3):350-360. doi: 10.5217/ir.2021.00049. Epub 2021 Jul 23. Intest Res. 2022. PMID: 34289648 Free PMC article.
279 results